On May 9, 2025, UBS analyst Dan Leonard announced an adjustment in the price target for Bio-Techne (TECH, Financial), lowering it from $95.00 to $70.00. Despite this significant decrease in the price target, UBS maintains a 'Buy' rating on the stock.
The revised price target represents a -26.32% change from the previous target. The decision to adjust the target price comes as UBS continues to evaluate Bio-Techne's market performance and future prospects.
Bio-Techne (TECH, Financial), traded on NASDAQ, remains a stock of interest for investors who are advised to consider the updated price target when making investment decisions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for Bio-Techne Corp (TECH, Financial) is $73.28 with a high estimate of $95.00 and a low estimate of $51.00. The average target implies an upside of 46.73% from the current price of $49.94. More detailed estimate data can be found on the Bio-Techne Corp (TECH) Forecast page.
Based on the consensus recommendation from 16 brokerage firms, Bio-Techne Corp's (TECH, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Bio-Techne Corp (TECH, Financial) in one year is $86.56, suggesting a upside of 73.33% from the current price of $49.94. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Bio-Techne Corp (TECH) Summary page.
